Detailed Narrative
H1 2025 Performance and Revised Outlook
Novo Nordisk delivered strong financial results in the first half of 2025, with sales growing 18% and operating profit increasing 29% at constant exchange rates. This performance was driven by both U.S. and International Operations, significantly expanding the patient base for diabetes and obesity treatments. However, the company revised its full-year 2025 sales and operating profit guidance downwards, attributing the change to lower growth expectations for Wegovy and Ozempic in the U.S. and Wegovy in certain international markets.
U.S. GLP-1 Market Dynamics and Compounding Impact
The U.S. market for GLP-1s continues to be influenced by the prevalence of compounded versions, with an estimated 1 million patients using them. This has impacted Wegovy's uptake, particularly in the cash channel, where penetration is around 10% of total prescriptions. Despite the FDA grace period expiration, unlawful compounding persists. Novo Nordisk is actively pursuing legal actions and increasing dialogue with the FDA to address this, while also expanding direct-to-patient initiatives like NovoCare Pharmacy.
International Operations Growth and China Dynamics
International Operations sales grew 19% at CER, with obesity care sales surging 125%, driven by Wegovy. Wegovy has now launched in approximately 35 countries, with over 15 new launches this year. However, GLP-1 diabetes sales in Region China were lower than expected due to wholesaler inventory adjustments, though the company maintains strong market share and confidence in the long-term potential given the high unmet need.
Advancements in R&D Pipeline
The R&D pipeline saw significant progress, including the advancement of subcutaneous and oral amycretin into Phase III for weight management, and the initiation of the REDEFINE 11 Phase IIIb trial for CagriSema. Regulatory milestones include a positive EMA opinion for Ozempic in peripheral arterial disease and submissions for Wegovy MASH in Japan and semaglutide 7.2mg in the EU. The company also completed a Phase II trial for Coramitug in ATTR cardiomyopathy, with Phase III expected to start in 2025.
Leadership Transition and Strategic Focus
Lars Fruergaard Jørgensen is stepping down as CEO, with Mike Doustdar assuming the role. Accompanying this transition are executive management changes, including Martin Lange becoming Chief Scientific Officer and Head of a unified R&D organization. The new leadership emphasizes a sharpened strategic focus on diabetes and obesity, enhanced commercial execution, operational efficiency, and reallocating resources to drive innovation and growth.
Capacity Expansion and Long-Term Capital Allocation
Novo Nordisk continues significant investments in manufacturing capacity, with capital expenditure expected to be around DKK 65 billion in 2025. These investments are primarily for API production and fill/finish capacity for current and future injectable and oral products. Management indicated that CapEx is nearing its peak, with a gradual decline expected as major projects conclude, and a long-term maintenance CapEx to sales ratio historically around 5%.